Dear Friend,

This year Democracy Now! is celebrating our 25th anniversary—that's 25 years of bringing you fearless, independent reporting. Since our very first broadcast in 1996, Democracy Now! has refused to take government or corporate funding, because nothing is more important to us than our editorial independence. But that means we rely on you, our audience, for support. Please donate today in honor of our 25th anniversary and help us stay on air for another 25 years. We can't do our work without you. Right now, a generous donor will even DOUBLE your gift, which means it’ll go twice as far! This is a challenging time for us all, but if you're able to make a donation, please do so today. Thank you and remember, wearing a mask is an act of love.
-Amy Goodman

Non-commercial news needs your support.

We rely on contributions from you, our viewers and listeners to do our work. If you visit us daily or weekly or even just once a month, now is a great time to make your monthly contribution.

Please do your part today.


European Nations Resume Using AstraZeneca COVID-19 Vaccine After Blot Clot Fears

HeadlineMar 19, 2021

About a dozen nations, including Germany, France, Italy and Spain, have resumed use of Oxford’s AstraZeneca vaccine, after Europe’s top regulator declared the shots safe and effective. The European Medicines Agency investigated 25 cases of rare blood clots among some 20 million people who’ve received AstraZeneca inoculations. It’s not known whether the vaccine caused the blood clots, and health officials say its benefits far outweigh its risks.

Meanwhile, the Biden administration said it plans to ship about 4 million doses of U.S.-made AstraZeneca vaccine to Mexico and Canada. The vaccine is not yet approved for use in the United States, and millions of vials have been piling up in U.S. warehouses, prompting criticism of “vaccine hoarding.” The White House says the vaccine shipments would have to be repaid, effectively making them a loan.

The original content of this program is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 United States License. Please attribute legal copies of this work to Some of the work(s) that this program incorporates, however, may be separately licensed. For further information or additional permissions, contact us.

Non-commercial news needs your support

We rely on contributions from our viewers and listeners to do our work.
Please do your part today.
Make a donation